...
首页> 外文期刊>DNA and Cell Biology >Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance
【24h】

Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance

机译:MiR-23b-3p,miR-195-5p,miR-656-5p和miR-340-5p的缺陷涉及HER2阳性乳腺癌细胞的抗性抗性和系统生物学方法,预测其抗性的目标

获取原文
获取原文并翻译 | 示例
           

摘要

Resistance to trastuzumab has become a limiting factor for therapeutic efficacy of human epidermal growth factor 2 (HER2)-positive breast cancer. Different expression levels of miRNAs in cancer cells have been associated with poor prognosis and response to chemotherapy. The aim of this study was to evaluate miRNAs that were thought to be associated with HER2-positive breast cancer chemoresistance. In this study, the relative expression of candidate miRNAs to U6 RNA was evaluated in trastuzumab-resistant and trastuzumab-sensitive cells using relative real-time PCR. Our results demonstrated that miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p were significantly dysregulated. For the first time in this study, these miRNAs were identified to be involved in trastuzumab resistance. TargetScan and miRDB were then used for predicting the potential targets of the candidate miRNAs. Our results also revealed that the predicted potential targets of these miRNAs were strongly associated with drug resistance pathways. As a relative expression of candidate miRNAs was statistically different in trastuzumab-resistant and trastuzumab-sensitive cells, their potential targets were involved in drug resistance pathways. We strongly hypothesized the dysregulation of miRNAs as a possible mechanism of trastuzumab resistance. We also assumed that the strategic manipulation of these regulatory networks might be a possible therapeutic strategy to improve the results of chemotherapy for this resistance. However, more research is needed to evaluate the role of these miRNAs in the acquisition of trastuzumab resistance.
机译:对曲妥珠单抗的抗性已成为人表皮生长因子2(HER2) - 阳性乳腺癌的治疗效果的限制因素。癌细胞中miRNA的不同表达水平与预后差和化疗反应有关。本研究的目的是评估被认为与Her2阳性乳腺癌化学患者有关的miRNA。在该研究中,使用相对实时PCR在曲据抗性和曲妥救卢敏感细胞中评价候选miRNA对U6 RNA的相对表达。我们的结果表明,MIR-23B-3P,MIR-195-5P,MIR-656-5P和MIR-340-5P显着失望了。在本研究中首次,鉴定了这些miRNA涉及曲妥珠单抗抗性。然后用于预测候选MiRNA的潜在目标的目标。我们的结果还显示出这些miRNA的预测潜在目标与耐药途径密切相关。随着候选MiRNA的相对表达在抗曲扣和曲妥珠敏敏细胞中统计学不同,它们的潜在靶标涉及耐药途径。我们强烈假设miRNA的失调作为曲妥珠猴的可能机制。我们还认为,这些监管网络的战略操纵可能是改善这种抵抗力化疗的化疗结果的可能治疗策略。然而,需要更多的研究来评估这些miRNA在获取曲据抵抗的情况下的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号